2019 ISGEDR Meeting – 29th to 31st August
Giessen 2019 – Day 1 Photo Gallery
DOG-Genetik
Sektion Genetische Ophthalmologie
der Deutschen Ophthalmologischen Gesellschaft
ISGEDR 2019 – Final Programme
You can download the ISGEDR 2019 – Final Programme in PDF form HERE
21st Meeting of the International Society for Genetic Eye Diseases & Retinoblastoma a joint Meeting with Section Genetics of the German Opthalmological Society (DOG)
Meeting Details
The meeting is sponsored by the International Society for Genetic Eye Diseases and Retinoblastoma in association with the German Ophthalmological Society (DOG)
Course Description
The ISGEDR Meeting brings together researchers and clinicians interested in various aspects of ocular genetics to exchange and learn about the latest developments in the field. The meeting is comprised of presentations of original research by meeting participants, as well as plenary sessions and symposia addressing current topics by distinguished invited speakers. The meeting also features named lectureships given by world-renowned specialists in the field of ophthalmic genetics and retinoblastoma.
Target Audience
The meeting will cater for a variety of audiences including general ophthalmologists, pediatric ophthalmologists, retina specialists as well as residents-in-training. Genetic counselors with an interest in eye diseases will find it equally beneficial. Molecular geneticists who have an interest in ocular disease and researchers in the field will find it an excellent venue to present their work and learn about that of others. Ophthalmologists and oncologists who treat patients with retinoblastoma will find the meeting sessions well organized to discuss the latest in diagnosis and management of patients with this most common pediatric eye tumor.
Objectives
At the end of the meeting the participants will be able to:
- Discuss the latest advances in gene therapy of inherited eye diseases
- Discern the differences between different current modalities of genetic testing
- Decide on the appropriate therapy for different forms and stages of retinoblastoma
- Detect the most prominent imaging features of inherited retinal diseases
- Recognize newly defined forms of retinal disorders and other genetic diseases of the eye
For more information, please contact the meeting office
PD Dr. Markus Preising
+49-641-985-43837
markus.preising@uniklinikum-giessen.de
Scientific Programme
This is a Scientific Programme for the 2019 ISGEDR meeting
Thursday, 29th August
8.00 h |
|
Onsite registration opens |
8.30 h – 09.00 h |
|
Welcome |
|
Prof. Dr. Birgit Lorenz |
President of ISGEDR Speaker of the Section Genetics of the German Ophthalmological Society (DOG) Head and Chairman of the Department of Ophthalmology, Justus-Liebig University Giessen and University Medical Center Giessen and Marburg GmbH, Giessen Campus |
|
Prof. Dr. Joybrato Mukherjee |
President of the Justus-Liebig University Giessen President elect of the Germany Academic Exchange Service (DAAD) |
|
Prof. Dr. Wolfgang Weidner |
Dean of the Medical Faculty, Justus Liebig University, Giessen |
|
Prof. Dr. Andreas Böning |
Chief Medical Officer, University Medical Center Giessen and Marburg GmbH, Giessen Campus |
|
|
|
09.00 h – 10.50 h |
1. Session |
Performing And Communicating Molecular Diagnostics Chair: Hanno Bolz, David Mackey |
09.00 h |
Bolz, Hanno Jörn, Frankfurt, Germany |
T01: NGS: Diagnostic opportunities and challenges of gene panel, whole-exome and whole-genome sequencing |
09.20.h |
Mackey, David,Subiaco, Australia |
T02: Predictive testing in glaucoma |
09.40 h |
Capasso, Jenina,Philadelphia, USA |
T03: We need more genetic counselors! |
10.00 h |
Arno, Gavin, London, United Kingdom |
O01: Interrogation of the 100,000 genomes project ophthalmic disease cohort reveals novel genes, new associations and previously undetectable mutations |
10.10 h |
Debenedictis, Meghan,Cleveland, USA |
O02: The value of CNV analysis for inherited retinal diseases |
10.20 h |
Hufnagel, Robert,Bethesda, USA |
O03: Modeling gene constraint in disease populations for clinical molecular diagnostics |
10.30 h |
Kellner, Ulrich,Siegburg, Germany |
O04: DNA testing in a series of 944 patients with inherited retinal dystrophies from a single german reference center |
10.40 h |
Wells, Kirsty, Helsinki, Finland |
O05: Enhancing diagnostic performance in inherited retinal diseases through advances in high resolution copy number detection and RPGR ORF15 sequencing |
|
|
|
|
|
Associated Posters |
|
Lei, Bo, Zhengzhou, Henan, China |
P01: Whole-exome sequencing identifies a novel homozygous missense variant in REEP6 in a retinitis pigmentosa patient complicated with macular hole |
|
Pantrangi, Madhulatha,Marshfield, USA |
P02: Shaping ‘PreventionGenetics’ comprehensive inherited retinal disorder panel for the clinical setting and to improve diagnostic yield |
|
Chan, Choi Mun, Singapore, Singapore |
P03: Genetic testing for macular dystrophies : The Singapore National Eye Centre experience |
|
|
|
10.50 h – 11.20 h |
|
Coffee Break |
|
|
Poster Session |
|
|
|
11.20 h – 13.00 h |
2. Session |
ClinicalStudies in Gene Therapy I Chair: Francesca Simonelli, Juliana Sallum |
11.20 h |
Leroy, Bart P, Ghent,Belgium |
T04: Safety & Efficacy of Antisense Oligonucleotide Therapy (QR-110) in LCA10 Patients with the c.2991+1655A>G Allele in CEP290 |
11.40 h |
Sahel, José-Alain, Paris, France |
T05: Leber Hereditary Optic Neuropathy: Gene Therapy for an Ultra-Orphan Blinding Disease |
|
|
|
|
|
Phenotypes – Free Papers Chair: Francesca Simonelli, Juliana Sallum |
12.00 h |
Brooks, Brian, Bethesda,USA |
O06: Homozygous frameshift mutations in FAT1 cause a syndrome characterized by colobomatous-microphthalmia, ptosis, nephropathy and syndactyly |
12.10 h |
Escher, Pascal, Bern, Switzerland |
O07: Molecular and cellular mechanisms in NR2E3-linked retinal degenerations |
12.20 h |
Grubich Atac, David, Schlieren, Switzerland |
O08: ATOH7 loss-of-function mutations in a family with hypoplasia of the optic nerve |
12.30 h |
Munier, Francis,Lausanne, Switzerland |
O09: Prevention of intravitreal melphalan-induced chorioretinopathy: identification of potential risk factors. |
12.40 h |
Ruddle, Jonathan,Parkville, Australia |
O10: The genetic and clinical landscape of nanophthalmos in an Australian cohort |
12.50 h |
Chaudhuri, Zia, Delhi, India |
O11: Pedigree analysis of familial primary concomitant horizontal strabismus in a South Asian population |
|
|
|
|
|
Associated Posters |
|
Abdel-Rahman, Mohamed,Columbus, USA |
P04: Assessment of the clinical phenotype of BAP1germline whole gene and large deletions |
|
Branham, Kari, Ann Arbor, USA |
P05: Suspicion for ABCA4-related retinal dystrophy: Clues beyond the typical Stargardt Phenotype |
|
Bryjova, Barbara,Giessen, Germany |
P06: Misinterpretation of an OMD phenotype from a common sequence variation in RP1L1 in a family with multiple sclerosis |
|
Ehrenberg, Miriam, Petach Tikva, Israel |
P07: Double struggle |
|
Everett, Lesley, San Francisco, USA |
P08: Ocular findings in two patients with vascular smooth muscle myopathy secondary to ACTA2 mutations |
|
Ibanez Iv, Manuel Benjamin, Philadelphia, USA |
P09: Stargardt misdiagnosis: How ocular genetics helps |
|
Kameya, Shuhei, Inzai, Japan |
P10: A novel homozygous in-frame deletion of GNAT1 gene cause golden discolouration of the fundus and reduced dark-adapted ERG similar to that of Oguchi disease in a Japanese family |
|
Majander, Anna, Helsinki, Finland |
P11: Clinical characteristics of early onset retinal dystrophy in association with the TULP1 c.148delG mutation |
|
Mauring, Laura,Strasbourg, France |
P12: Alström syndrome with atypical retinal dystrophy and inheritance |
|
Prasov, Lev, Flint, USA |
P13: Clinical and genetic features of Jalilli syndrome in a North American patient cohort |
|
Starosta, Daniela Aneta, Giessen, Germany |
P14: Phenotype in five related patients with isolated optic nerve atrophy associated with a heterozygous mutation in the spastic paraplegia gene 7. |
|
|
|
13.00 h – 14.30 h |
|
Lunch Break |
|
|
Poster Session |
|
|
|
14.30 h – 15.50 h |
3. Session |
Stem Cells Chair: Mike Karl, Eyal Banin |
14.30 h |
Bachmann, Björn, Cologne,Germany |
T06: Treatment options for limbal stem cell deficiency in inhereted eye diseases |
14.50 h |
Karl, Mike, Dresden, Germany |
T07: Towards modeling of neuronal and glial pathologies in retinal organoids |
15.10 h |
Banin, Eyal, Jerusalem, Israel |
T08: Derivation of RPE cells from human embryonic stem cells (hESCs): The journey from basic research to clinical application |
15.30 h |
Battu, Rajani, Bangalore, India |
O12: Differentiation and characterization of RPE from hiPSC and its subretinal transplantation in RCS rats |
15.40 h |
Galardi, Angela,Rome, Italy |
O13: Proteomics profiling of retinoblastoma derived exosomes |
|
|
|
15.50 h – 16.20 h |
|
Coffee Break |
|
|
Poster Session |
|
|
|
16.20 h – 17.05 h |
|
Franceschetti Medal & Lecture |
16.20 h |
Albert Franceschetti, Lausanne, Switzerland |
Introduction to the Franceschetti Medal & Lecture |
16.35 h |
Sieving, Paul, Bethesda,USA |
L1: Clinical features and molecular basis of X-linked retinoschisis: From mechanism to therapy. |
|
|
|
17.05 h – 18.35 h |
4. Session |
Biomarkers for Substantiating Success in Treatment Chair: Tomas Aleman, Michael Hoffmann |
17.05 h |
Aleman, Tomas, Philadelphia,USA |
T09: AAV2-hCHM subretinal delivery to the macula in choroideremia: performance of outcome measures |
17.25 h |
Hoffmann, Michael,Magdeburg, Germany |
T10: Plasticity and its limits – Cortical visual field representations in achromatopsia |
17.45 h |
Gocho, Kiyoko, Inzai, Japan |
T11: High-resolution retinal imaging analysis in female carriers of choroideremia |
18.05 h |
Lima de Carvalho Jr, Jose Ronaldo,Recife, Brazil |
O14: Multimodal imaging of patients with Best Vitelliform Macular Dystrophy (BVMD): a 4-year follow-up study. |
18.15 h |
Sallum, Juliana, Sao Paulo, Brazil |
O15: Characterization of the Brazilian ARSACS phenotype: clinical, ophthalmological, neuroimaging, and genetic features of fourteen cases |
18.25 h |
Studer, Fouzia,Strasbourg, France |
O16: Retinal implantation with Argus II artificial retina in 3 patients with Bardet-Biedl syndrome |
|
|
|
|
|
Associated Posters |
|
Tanrikulu, Özgün,Giessen, Germany |
P15: Analysis of outer retinal layer alterations in patients with RPE65deficiency using Optical Coherence Tomography A-Scan-Analysis |
|
|
|
19.30 h |
|
Gala Dinner |
|
|
Restaurant Heyligenstaedt, Aulweg 41, 35392 Gießen |
Friday, 30th August
8.00 h |
|
Onsite Registration |
|
|
|
8.30 h – 10.00 h |
5. Session |
Luxturna Therapy – Recent Developments Chair: Stephen Russell, Paul Sieving |
08.30 h |
Leroy, Bart P, Ghent, Belgium |
T12: voretigene neparvovec for RPE65-related inherited retinal dystrophies: The Philadelphia Experience |
08.45 h |
Drack, Arlene, Iowa City, USA |
T13a: How long does gene therapy last? 4 Year followup and adult versus pediatric outcomes of phase 3 voretigene neparvovec trial in RPE65–associated LCA/inherited retinal disease |
|
|
T13b: Electrophysiology following subretinal treatment with voretigene neparvovec (Luxturna) |
09.00 h |
Simonelli, Francesca,Naples, Italy |
T14: Our experience with gene therapy approaches for RPE65 inherited retinal diseases |
09.15 h |
Lorenz, Birgit,Giessen, Germany |
T15: Country specific problems to get started with EMA-approved gene therapy with Luxturna |
09.30 h |
Chung, Daniel C., Philadelphia, USA |
T16: The post-authorization safety study of voretigene neparvovec-rzyl |
09.45 h |
|
Panel Discussion |
|
|
|
10.00 h – 10.30 h |
|
Coffee Break |
|
|
Poster Session |
|
|
|
10.30 h – 11.15 h |
|
Ellsworth Lecture |
10.30 h |
Francis Munier, Lausanne, Switzerland |
Introduction to Ellsworth Lecture |
10.45 h |
Desjardins, Laurence,Rochefort En Yvelines, France |
L2: Retinoblastoma around the world in 2019 |
|
|
|
11.15 h – 13.25 h |
6. Session |
Precision Care for Children with Retinoblastoma Chair: Brenda Gallie, Dietmar Lohmann |
11.15 h |
Di Giannatale, Angela,Rome, Italy |
T17: Proteomics for biomarker identification in retinoblastoma liquid biopsy |
11.35 h |
Cole, Trevor, Birmingham, United Kingdom |
T18: The current and future role of cell free DNA analysis in the management of retinoblastoma. |
11.55 h |
Gallie, Brenda,Toronto, Canada |
T19: Disruptive innovations to reach precision retinoblastoma care |
12.15 h |
Soliman, Sameh,Toronto, Canada |
T20: Optimizing focal laser photocoagulation therapy for retinoblastoma |
12.35 h |
Everett, Lesley, San Francisco, USA |
O17: Retinoblastoma treatment in the age of intra-vitreal and intra-arterial chemotherapy: the UCSF experience |
12.45 h |
De Jong, Marcus,Amsterdam, Netherlands |
O18: Screening for pineal trilateral retinoblastoma revisited: a meta-analysis |
12.55 h |
Menges, Julia, Essen, Germany |
O19: A human organoid-based model for retinoblastoma |
13.05 h |
Tsygankov, Alexander,Moscow, Russian Federation |
O20: New retinoblastoma cell culture establishment and drug resistance assessment |
13.15 h |
White, Jaclyn, Clayfield, Australia |
O21: Delay in the diagnosis of retinoblastoma: the role of parents and practitioners |
|
|
|
|
|
Associated Posters |
|
Hattori, Hiroyoshi,Nagoya, Japan |
P16: Bilateral retinoblastoma with 13q-syndrome in a patient carrying an X;13 balanced translocation without rearrangement of the RB1 gene |
|
|
|
13.25 h – 14.05h |
|
Lunch Break |
|
|
Poster Session |
|
|
|
14.05 h – 14.45 h |
7. Session |
Clinical Studies in Gene Therapy II Chair: Birgit Lorenz, Bart Leroy |
14.05 h |
MacLaren, Robert,Oxford, UK |
T21: Gene therapy for X-linked retinitis pigmentosa caused by mutations in RPGR |
14.25 h |
Russell, Stephen, Iowa City, USA |
T22: Surgical challenges and outcomes with voretigene neparvovec (Luxturna) |
|
|
Treatment-associated Posters |
|
Alfarsi, Ammar,Muscat, Oman |
P17: Intravitreal ranibizumab (Lucentis®) in the treatment of non-leaking macular cysts in retinal dystrophy |
|
Andrassi-Darida, Monika, Giessen, Germany |
P18: Laser photocoagulation for hemorrhagic retinopathy in a newborn with Norrie disease |
|
Cui, Xuan, New York, USA |
P19: Enhancing glycolytic metabolism with gene therapy and a small molecule drug attenuates neurodegeneration |
|
Reschke, Madlen,Essen, Germany |
P20: Individual treatment of an infant with severe conjunctivitis lignosa (CL) and other systemic manifestations of plasminogen deficiency, caused by a compound mutation of the PLG gene |
|
|
|
15.00 h |
|
Excursion by bus |
|
|
Marburg |
|
|
|
19.30 h |
|
Gala Dinner |
|
|
Schloß Rauischholzhausen, Ebsdorfer Grund |
Approx. 23.00 h |
|
Return to Giessen |
Saturday, 31st August
8.00 h |
|
ISGEDR General assembly |
|
|
|
9.00 h – 10.30 h |
8. Session |
Secondary Cancer and Survival in Retinoblastoma Chair: Petra Ketteler, Ashwin Reddy |
09.00 h |
Ketteler, Petra, Essen,Germany |
T23: The Impact of the Type Of Predisposing RB1Variants on the Incidence of Malignancies |
09.20 h |
Moll, Annette, Amsterdam, Netherlands |
T24:Retinoblastoma and second primary malignancies: a Dutch overview and update |
09.40 h |
Lohmann, Dietmar,Essen, Germany |
O22: Understanding and predicting tumor risk in heritable retinoblastoma |
09.50 h |
Abdel-Rahman, Mohamed,Columbus, USA |
O23: Study of genetic predisposition to uveal melanoma |
10.00 h |
Reddy, M. Ashwin, London, United Kingdom |
O24: Prognostic information for mosaic and high penetrant carriers of RB1 mutations |
10.10 h |
Shah, Parag, Coimbatore, India |
O25: Outcomes of RB1 gene testing from blood samples of 113 retinoblastoma survivors and their families (398 in total) collected on a single day at Aravind Eye Hospital, Coimbatore, India. |
10.20 h |
van Hoefen Wijsard, Milo, Amsterdam, Netherlands |
O26: Type of RB1mutation and age at diagnosis of familial retinoblastoma screened from birth. |
|
|
|
|
|
Associated Posters |
|
Janic, Ana, Toronto, Canada |
P21: Patient-reported outcome measures for retinoblastoma: A scoping review |
|
Jansen, Robin,Amsterdam, Netherlands |
P22: Should postlaminar optic nerve tumor invasion into the outer layers be considered a risk-factor for leptomeningeal spread of retinoblastoma? A case report and review of the literature |
|
Saakyan, Svetlana,Moscow, Russian Federation |
P23: Long-term follow-up after retinoblastoma: secondary malignancy. |
|
|
|
10.30 h – 11.00 h |
|
Coffee Break |
|
|
Poster Session |
|
|
|
11.00 h – 12.30 h |
9. Session |
Patients in Focus Chairs: Christina Fasser, Helene Dollfus |
11.00 h |
Dollfus, Helene,Strasbourg, France |
T25: What could be the EYE-EYE role in rare eye diseases care in Europe? |
11.15 h |
Fujinami, Kaoru,Toyko, Japan |
T26: Clinical and genetic characteristics of East Asian patients with inherited retinal disorders |
11.30 h |
Dimaras, Helen,Toronto, Canada |
T27: Achieving meaningful patient research partnership: development of the Canadian Retinoblastoma Research Advisory Board |
11.45 h |
Gallie, Brenda,Toronto, Canada |
T28: DEPICT HEALTH “full view for life” for circle of care including families will empower research |
11.55 h |
Badura, Franz,Amberg, Germany |
T29: The PRO RETINA patient registry |
12.05 h |
Fasser, Christina,Zürich, Switzerland |
T30: Leave no one behind –Patient’s perspective |
12.15 h |
|
Panel Discussion |
|
|
|
|
|
Associated Posters |
|
Escher, Pascal, Bern,Switzerland |
P24: The Swiss Registry of Rare Eye Diseases |
|
Nanos, Stephanie, Toronto, Canada |
P25: The Canadian Retinoblastoma Research Registry |
|
Ristevski, Ivana,Toronto, Canada |
P26: The top 10 retinoblastoma research priorities in canada as determined by patients, clinicians and researchers |
|
|
|
12.30 h – 13.15 h |
|
François-Lecture |
12.30 h |
Bart Leroy, Ghent, Belgium |
Introduction to the François-Lecture |
12.45 h |
Lorenz, Birgit, Giessen,Germany |
L3: Biomarkers in IRDs: scientifically valid – clinically relevant |
|
|
|
13.15 h – 14.00 h |
|
Lunch Break |
|
|
Poster Session |
|
|
Microphthalmia – Anophthalmia – Coloboma – Developmental Failures |
|
Bacci, Giacomo, Firenze, Italy |
P27: Novel mutations in MFRPand PRSS56 genes associated to posterior microphthalmos |
|
Balikova, Irina, Gent, Belgium |
P28: Mendeliome in patients with microphthalmia, anophthalmia and coloboma – results and challenges |
|
Friedburg, Christoph,Giessen, Germany |
P29: Early onset severe retinal dystrophy with irido-chorioretinal coloboma with optic disc dysplasia and macular hypoplasia in one eye due to a heterozygous GDF6-mutation |
|
Pfäffli, Oliver,Zürich, Switzerland |
P30: Genotype phenotype correlation in a case series of nanophthalmos |
|
Ramzan, Khushnooda,Riyadh, Saudi Arabia |
P31: Novel phenotype-genotype correlation with PEX6 gene in Saudi patients with Heimler syndrome |
|
Takitani, Guilherme,São Paulo – Sp, Brazil |
P32: Microcephaly and chorioretinopathy associated with TUBGCP4 mutation |
|
|
|
14.00 h – 15.00 h |
10. Session |
Understanding Treatment Effects from Natural History Studies Chair: Elias Traboulsi, Hendrik Scholl |
14.00 h |
Scholl, Hendrik, basel, Switzerland,Switzerland |
T31: Natural history of the progression of atrophy secondary to Stargardt disease (ProgStar) study |
14.20 h |
Hahn, Leo, Amsterdam, Netherlands |
O27: Long-term follow-up, phenotypic and genetic spectrum of patients with juvenile X-linked retinoschisis in the Netherlands |
14.30 h |
Nguyen, Xuan-Thanh-An, Leiden, Netherlands |
O28: The disease course of rhodopsin (RHO)-associated retinitis pigmentosa (RP): a follow-up study |
14.40 h |
Senatore, Alfonso,Durham, USA |
O29: “Further evaluation of a simple perimetric approach to the differential diagnosis between blue cone monochromacy (BCM) and achromatopsia (ACHM)” |
14.50 h |
Testa, Francesco, Napoli, Italy |
O30: Longitudinal natural history study in patients with Retinitis Pigmentosa in preparation for gene therapy clinical trials |
|
|
|
15.00 h – 15.30 h |
|
Coffee Break |
|
|
Poster Session |
|
|
Glaucoma |
|
Hosono, Katsuhiro, Hamamatsu,Japan |
P33: A case of childhood glaucoma with a combined partial monosomy 6p25 and partial trisomy 18p11 due to an unbalanced translocation |
|
Lang, Elena, Zurich, Switzerland |
P34: Genotypic and phenotypic characterization of childhood glaucoma |
|
Naruse, Sho, Kitakyushu City, Japan |
P35: Development of glaucoma after early cataract surgery in case of oculo-facio-cardio-dental syndrome |
|
Pisuchpen, Phattrawan,Philadelphia, USA |
P36: The Robison D. Harley, MD Childhood Glaucoma Research Network (CGRN) International Pediatric Glaucoma Registry |
|
|
|
|
|
Foveal Hypoplasia |
|
Chaudhuri, Zia, New Delhi, India |
P37: Novel variant in SLC38A8 gene segregating with foveal hypoplasia in an autosomal recessive South Asian family |
|
Dumitrescu, Alina, Iowa City, USA |
P38: Genotype-Phenotype Correlation in Patients with Albinism |
|
Kondo, Hiroyuki, Kitakyushu, Japan |
P39: Correlation between genotype-phenotype in patients with autosomal dominant idiopathic foveal hypoplasia associated with PAX6 mutations |
|
Kröll-Hermi, Ariane,Strasbourg, France |
P40: Zebrafish, as a useful model to validate human eye candidate diseases genes. |
|
|
|
15.30 h – 16.50 h |
11. Session |
Gene and Cell based Therapies Chair: Knut Stieger, Volker Busskamp |
15.30 h |
Ader, Marius, Dresden, Germany |
T32: Photoreceptor transplantation into the mammalian retina |
15.50 h |
Stieger, Knut, Giessen, Germany |
T33: DNA repair mechanisms in photoreceptors |
16.10 h |
Busskamp, Volker,Dresden, Germany |
T34: Forward programming of human stem cells to photoreceptors |
16.30 h |
Müller, Brigitte,Giessen, Germany |
O31: DNA repair after ISce-I mediated DSB in photoreceptors and RPE cells following AAV mediated gene transfer in vivo |
16.40 h |
Wimmer, Tobias,Giessen, Germany |
O32: A bioluminescence resonance energy transfer based sensor for the precise determination of non-homologous end joining DNA repair events |
|
|
|
|
|
Associated Posters |
|
Weller, Maria, Giessen,Germany |
P42: First steps to a MMEJ genome editing approach correcting CLN3/Cln3deltaEx7/8 |
|
|
|
16.50 h |
|
Farewell |
17.00 h |
|
End of conference |
General Information
General Information
This course is accredited for Continuing Medical Education (CME) by the Landesärztekammer Hessen (LÄKH) and the European Union of Medical Specialists (UEMS).
In keeping with CMA Guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs of the course and not to individual speakers.
Location
The 2019 ISGEDR conference will be held in Giessen, Germany. Giessen is a regional centre of Middle Hesse located in the center of Germany. One can easily walk from the conference venue located close to the downtown area to many historical sites, hotels, restaurants, and the shopping area. The main station is at 10 min walking distance.
Learn more about Giessen and all it has to offer by clicking here.
The conference will be held at Justus-Liebig University in the great lecture hall of the Faculty of Medicine inside the newly refurbished teaching building (Klinikstrasse 29).
Justus-Liebig University, Giessen, Germany
Thursday 29th
Friday 30th
The Gala Dinner will be on August 29, and held in the former machine house of the Heyligenstaedt Company (Aulweg 41).
On August 30, an excursion to Marburg is scheduled. Marburg is a medievial town with a renonwed university. The participants will be guided through the old town and to the castle of the landgrave.
ISGEDR Membership and Registration Form
Meeting Sponsors
Meeting Supporter
This 2019 ISGEDR meeting is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation)
Sponsors
The content of this meeting is independent of commercial interests.
Any conflict of interest by the scientific organizers or the presenters will be disclosed in the related presentations, in the meeting proceedings, and on the meeting website.
The International Society for Genetic Eye Disease & Retinoblastoma in addition wishes to thank the following sponsors who have generously supported the 2019 ISGEDR Meeting:
Platinum Sponsor*
Gold Sponsors*
*Sponsor Support: Gold €1000-€2000, Platinum €2000+
Accommodation
Hotels
The following is a list of a few hotels that can be found in the downtown area. We have not negotiated set rates for our conference. The selected a hotels are located in walking distance to the conference venue or easy to reach by bus. Close distance hotels are not necessarily the best choice but acceptable. Giessen Tourist Board will be happy to assist you and online booking agencies provide ratings for your decision. Prices are approximate single room rates per night. All prices in Germany include taxes. Tips are welcome but are a gesture of appreciation and not mandatory like in the US.
Hotel Name and Website
Location, Room Details and Distance
1. Parkhotel Friedrichstrasse
http://www.parkhotelgiessen.de/
Friedrichstrasse 1-3, 35392 Gießen
30 rooms – 95 EUR / night
0,4 km
2. Hotel Heyligenstaedt
https://www.restaurant-heyligenstaedt.de/
Aulweg 41, 35392 Gießen
20 rooms – 120 EUR / night
1.6 km
3. Hotel Alt Gießen
https://www.hotel-alt-giessen.de/de/hotel-alt-giessen.html
Westanlage 30-32, 35390 Gießen
33 rooms – 90 EUR / night
1.7 km
4. Best Western, Hotel Steinsgarten
https://www.bestwestern.de/hotels/Giessen/Best-Western-Plus-Hotel-Steinsgarten
Hein-Heckroth-Straße 20, 35390 Gießen
123 rooms – 125 EUR / night
2 km
5. Hotel am Ludwigsplatz
http://hotel-am-ludwigsplatz.de/
Ludwigsplatz 8, 35390 Gießen
37 rooms – 85 EUR / night
2 km
6. Parkhotel Sletz
https://www.parkhotel-sletz.de/en/home/
Wolfstraße 26, 35394 Gießen
20 rooms – 105 EUR / night
2.5 km
Bus line 1 – (Busstop: Wolfstrasse) destination Lützelinden
drop off Klinikstrasse, 5 min walk to venue
7. Hotel Tandreas
https://www.tandreas.de/de
Licher Str. 55, 35394 Gießen
20 rooms – 119 EUR / night
2.5 km
Bus line 2 – (Busstop Lutherberg) destination Bahnhof
drop off Central station (Bahnhof), 10 min walk to venue
8. Residenz Hotel Gießen
https://www.residenz-hotel-giessen.de/
Wiesecker Weg 12, 35396 Gießen
33 rooms – 90 EUR / night
3.3 km
Bus line 5, 371 – (Busstop Wiesecker Weg) destination Bahnhof
drop off Central station (Bahnhof), 10 min walk to venue
Gießen Tourist Board
https://www.giessen.de/Tourismus_und_Shopping/
Hotels (blue pins)
Events (red pins)
Conference Site (CS)
Teaching Building of the Medical Faculty of Justus-Liebig University
Klinikstrasse 29, 35392 Gießen, Germany
Gala Dinner (GD)
Thursday August 29, 2019
Restaurant Heyligenstaedt, Aulweg 41, 35392 Gießen, Germany
Gala Dinner
Friday August 30, 2019
Rauischholzhausen Castle, Schlosspark 1, 35085 Ebsdorfergrund, Germany
How to reach the meeting venue?
Transfer from Frankfurt (Main) Airport to Giessen
By Train – Deutsche Bahn AG
Take the commuter train (S8 / S9) from Frankfurt Airport (Frankfurt am Main Flughafen Local Trains) to Frankfurt Central Station (Frankfurt (Main) Hbf). Avoid ICE, IC trains and save money.
Change to Regional Express (RE, RB) trains from Frankfurt Central Station (Frankfurt (Main) Hbf) to Giessen Central Station
Online Search is available by Deutsche Bahn: Duration: 70 – 100 minutes | Ticket cost (adults): 16.00 € (single, all way to Giessen)
Note: Train tickets can be purchased at the ticket dispensers on track and online
By Taxi
Taxis with a taximeter are permanently available in front of the arrivals hall. Licensed taxis are beige and have a black and yellow sign “TAXI” on the top.
Duration: ± 44 minutes | Estimated cost: ±133 €
Mini Cars (available by appointment only)
Star Taxi-Minicar Tel: +49-641-33 33
Lahn City Car +49-641-82082
Fares on request, about 50% of taxi costs (Contact forms in German only)
Transfer from Giessen Central Station to Conference Venue
Walking
The venue is in 10 minute walking distance from the central station. Step out of the main entrance of the station, cross the bridge left hand and follow the street (Friedrichstrasse) passing the traffic lights (Frankfurter Strasse). Turn right at the bar protected gate and follow the street straight ahead by passing the Department of Ophthalmology (left side) straight through to next intersecting street (Klinikstrasse) by finally passing the venue (left side).
By Taxi
Social Programme